Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
Abstract Background Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and efficacy in a real-world setting. This study aims to assess how clinical o...
Saved in:
Main Authors: | Shaun J. Kilty, Andrea Lasso |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-04-01
|
Series: | Journal of Otolaryngology - Head and Neck Surgery |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40463-022-00570-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission
by: Mona Al-Ahmad, MD, FRCPC, et al.
Published: (2025-02-01) -
The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
by: Nicholas J. Campion, et al.
Published: (2023-09-01) -
Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis
by: Daiki Nakashima, MD, et al.
Published: (2025-05-01) -
Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach
by: Oliver Pfaar, et al.
Published: (2025-01-01) -
Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis
by: Andrew Thamboo, et al.
Published: (2021-03-01)